Biomedical Sciences
Global

Biomedical Sciences Experts

Bryan Roberts


biomedics
Aurigene 
San Marino

Biography

Bryan Roberts, Ph.D. has served on the Board of Directors since November of 2013. Bryan joined Venrock as a Kauffman Fellow in 1997. He is based in Venrock’s Palo Alto office and focuses on a broad range of healthcare investments. Bryan is currently Chairman of the Board of Directors of Achaogen (NASDAQ: AKAO), Castlight Health (NYSE: CSLT), Ironwood Pharmaceuticals (NASDAQ: IRWD), and Kyruus and also serves on the Board of several other companies, including 10X Genomics, Doctor on Demand, Grand Rounds, Intarcia, and Zeltiq (NASDAQ: ZLTQ). Past investments include Ariosa Diagnostics (acquired by Roche), athenahealth (NASDAQ: ATHN), CodeRyte (acquired by 3M), Ikaria (acquired by Madison Dearborn), Illumina (NASDAQ: ILMN), and Sirna Therapeutics (acquired by Merck). Bryan was named a Henry Crown Fellow by the Aspen Institute in 2006 and is the only healthcare investor to rank on Forbes’ Midas List six times, 2008 – 2014. Immediately prior to joining Venrock, Bryan received his Ph.D. in Chemistry & Chemical Biology from Harvard University. He previously held positions in corporate finance at Kidder, Peabody & Co and received his B.A. from Dartmouth College.

Research Interest

Bryan Roberts, Ph.D. has served on the Board of Directors since November of 2013. Bryan joined Venrock as a Kauffman Fellow in 1997. He is based in Venrock’s Palo Alto office and focuses on a broad range of healthcare investments. Bryan is currently Chairman of the Board of Directors of Achaogen (NASDAQ: AKAO), Castlight Health (NYSE: CSLT), Ironwood Pharmaceuticals (NASDAQ: IRWD), and Kyruus and also serves on the Board of several other companies, including 10X Genomics, Doctor on Demand, Grand Rounds, Intarcia, and Zeltiq (NASDAQ: ZLTQ). Past investments include Ariosa Diagnostics (acquired by Roche), athenahealth (NASDAQ: ATHN), CodeRyte (acquired by 3M), Ikaria (acquired by Madison Dearborn), Illumina (NASDAQ: ILMN), and Sirna Therapeutics (acquired by Merck). Bryan was named a Henry Crown Fellow by the Aspen Institute in 2006 and is the only healthcare investor to rank on Forbes’ Midas List six times, 2008 – 2014. Immediately prior to joining Venrock, Bryan received his Ph.D. in Chemistry & Chemical Biology from Harvard University. He previously held positions in corporate finance at Kidder, Peabody & Co and received his B.A. from Dartmouth College.

Global Experts from San Marino

Global Experts in Subject